Core Viewpoint - The company has announced significant changes in its governance structure, including the cancellation of the supervisory board and amendments to its articles of association, alongside updates on its financial performance and participation in national drug procurement programs [7][8][9][46]. Financial Performance - The company reported a 31.47% increase in revenue from the hygiene products segment compared to the same period last year, driven by rising demand for medical-grade sanitary napkins and increased promotional efforts [44]. - The company’s registered capital changed from RMB 42,399.7117 million to RMB 49,221.0016 million following the repurchase and cancellation of restricted stocks and the issuance of shares for asset acquisition [9][11]. Governance Changes - The supervisory board will be abolished, with its responsibilities transferred to the audit committee of the board of directors, in compliance with the revised Company Law and related regulations [8][9]. - Amendments to the articles of association include the removal of supervisory board provisions, updates on the responsibilities of the controlling shareholder, and the introduction of independent director sections [12][13][14]. Drug Procurement Participation - The company’s subsidiary, Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd., has participated in the national drug procurement process, with three products expected to be selected for the 11th batch of national drug centralized procurement [46]. - The procurement cycle for selected products will run until December 31, 2028, which could enhance the company's market presence and brand influence if contracts are signed and executed successfully [51].

Core Viewpoint - Qianjin Pharmaceutical (600479) announced that its subsidiary, Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd., participated in the 11th national centralized procurement organized by the National Organization for Drug Procurement Office, with three products expected to be selected for this procurement [1] Group 1 - Qianjin Xiangjiang Pharmaceutical is bidding for three products: Adenosylcobalamin Capsules, Fluvoxamine Tablets, and Dapoxetine Tablets [1]

Core Viewpoint - Qianjin Pharmaceutical announced that its subsidiary, Qianjin Xiangjiang Pharmaceutical, participated in the 11th batch of national centralized drug procurement, with three products expected to be selected for procurement [1] Group 1: Selected Products and Pricing - Adenosylcobalamin capsules are expected to be selected at a price of 4.88 yuan per box, primarily supplying Hunan, Guangxi, and Guizhou [1] - Fluvoxamine tablets are expected to be selected at a price of 7.14 yuan per box, primarily supplying Zhejiang, Fujian, and Chongqing [1] - Dopamine hydrazine tablets are expected to be selected at a price of 18.88 yuan per box, primarily supplying Sichuan, Hebei, Tianjin, and Ningxia [1] Group 2: Market and Sales Outlook - As of the end of Q3 2025, these products have not generated sales in the domestic market [1] - The procurement cycle for selected products will be from the execution date of the selection results until December 31, 2028 [1]